National and Kapodistrian University of Athens
Η έκφραση και ενεργοποίηση του PRARy, ως το προ-αποπτωτικό σύστημα μεταγωγής σήματος της δοξορουμπικίνης, στα κύτταρα καρκίνου προστάτη ( PC-3 cells) in vitro και στο τρισδιάστατο σύστημα καλλιέργειας κολλαγόνου τύπου Ι ( 3-D collagen system), παρουσία ή απουσία συν-καλλιέργειας οστεοβλαστών
Abstract
dc:descriptionPPAR-γ a member of the peroxisome proliferator-activated receptor family is overexpressed in tumors and several prostate cancer cell lines. In vitro and in vivo studies in cancers have implicated PPARγ ligands as inhibitors of cell growth and promoters of cell cycle arrest, apoptosis and/or differentiation in prostate cancer cell lines such as in PC-3 cell line. These ligands exert their anticancer effect via both “genomic” as well as “non-genomic” events. The non-genomic action of PPARγ ligands, including the activation of MAPK and PI3-K signaling pathways, is presently under intense investigation. However a crucial issue in patients with advanced prostate cancer is that osteoblastic metastases are hormone-independent and cytotoxic drug resistant. Therefore, we analyzed the ability of two PPAR-γ ligands 15dPGJ2 and rosiglitazone, a natural and a synthetic ligand of PPAR-γ respectively, to increase adriamycin effectiveness on cytotoxicity and to decrease the survival factor effect of osteoblast-related growth factor IGF-1 on adriamycin-induced apoptosis of PC-3 prostate cancer cells. Our studies revealed that the two ligands have opposing effects upon IGF-1 ability to develop cytotoxic drug resistance through early non-genomic effects, and especially through the IGF-1R signaling pathways which involve ERK1/2 and Akt. Since the IGF1.R signaling is probably the most important host tissue (bone) metastasis microenvironment-related survival signaling for prostate cancer cells, we conclude that PPARγ ligand effects on IGF1.R-mediated activation of ERK1/2 and AKT could have clinical implications for the management of androgen ablation-refractory and chemotherapy-resistant advanced prostate cancer with bone metastasis
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papageorgiou, Efstathia
- Παπαγεωργίου, Ευσταθία
Subjects
dc:subject × 18- Καρκίνος προστάτη
- Θειαζολιδινεδιόνες
- Απόπτωση
- Αδριαμυκίνη
- Μη γονιδιωματική δράση
- Οστεοβλάστες
- Οστικής μετάστασης, Μικροπεριβάλλον
- PPARγ
- Prostate cancer
- Thiazolidinediones
- Apoptosis
- Adriamycin
- Osteoblasts
- Bone microenvironment
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18339